Search results for "neoplasm invasiveness"

showing 10 items of 186 documents

DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma:…

2001

BACKGROUND The prognostic value of DNA ploidy, S-phase fraction (SPF) and K-ras-2 mutations in gastric carcinoma (GC) has not yet been clearly defined. The aim of this study was to clarify the association between biomolecular variables, tumor characteristics, and clinical outcome in GC patients. METHODS Resected specimens from a consecutive series of 69 patients with GC who underwent potentially curative surgery were studied prospectively. DNA ploidy and SPF were assessed by flow cytometry on multiple frozen tumor samples, whereas K-ras-2 mutations were detected by polymerase chain reaction followed by single-strand conformation polymorphism. All the patients involved in this study were fol…

MaleOncologyCancer ResearchPathologyStagingSettore MED/06 - Oncologia MedicaAneuploidyPolymerase Chain ReactionS Phaselaw.inventionRisk FactorslawProspective StudiesStage (cooking)Prospective cohort studyK-ras-2Polymorphism Single-Stranded ConformationalPolymerase chain reactionUnivariate analysisDNA NeoplasmMiddle AgedFlow CytometryPrognosisOncologyFemaleAdultmedicine.medical_specialtyPrognosiGastrectomyPredictive Value of TestsStomach NeoplasmsInternal medicineBiomarkers TumorCarcinomamedicineHumansNeoplasm InvasivenessSurvival analysisAgedNeoplasm Stagingbusiness.industryCarcinomaGastric carcinomaCancerAneuploidymedicine.diseaseSurvival AnalysisGenes rasDNA ploidyNeoplasm Recurrence LocalbusinessS-phase fraction
researchProduct

The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, …

2005

Purpose The aims of the TP53 Colorectal Cancer (CRC) International Collaborative Study were to evaluate the possible associations between specific TP53 mutations and tumor site, and to evaluate the prognostic and predictive significance of these mutations in different site, stage, and treatment subgroups. Patients and Methods A total of 3,583 CRC patients from 25 different research groups in 17 countries were recruited to the study. Patients were divided into three groups according to site of the primary tumor. TP53 mutational analyses spanned exons 4 to 8. Results TP53 mutations were found in 34% of the proximal colon tumors and in 45% of the distal colon and rectal tumors. They were assoc…

MaleOncologyCancer Researchmedicine.medical_specialtyPathologyRECTAL-CARCINOMATumor suppressor geneColorectal cancerLymphovascular invasionMICROSATELLITE INSTABILITYCELL LUNG-CANCERDNA Mutational AnalysisALLELIC LOSSDUKES STAGE-BMOLECULAR MARKERSInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineGenetic Predisposition to DiseaseNeoplasm InvasivenessStage (cooking)neoplasmsSurvival rateAgedNeoplasm Stagingbusiness.industryCOLON-CANCERMicrosatellite instabilityZINC-BINDING DOMAINExonsMiddle AgedWILD-TYPE P53medicine.diseaseAdenocarcinoma MucinousPrimary tumorSurvival RateOncologyChemotherapy AdjuvantMutationAdenocarcinomaFemaleZINC-BINDING DOMAIN; CELL LUNG-CANCER; DUKES STAGE-B; WILD-TYPE P53; GENETIC PATHWAYS; COLON-CANCER; MICROSATELLITE INSTABILITY; MOLECULAR MARKERS; RECTAL-CARCINOMA; ALLELIC LOSSGENETIC PATHWAYSTumor Suppressor Protein p53Colorectal NeoplasmsbusinessFollow-Up Studies
researchProduct

Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study

2018

Prognostic assessment of patients with hepatocellular carcinoma (HCC) at the time of diagnosis remains controversial and becomes even more complex at the time of restaging when new variables need to be considered. The aim of the current study was to evaluate the prognostic utility of restaging patients before proceeding with additional therapies for HCC. Two independent Italian prospective databases were used to identify 1,196 (training cohort) and 648 (validation cohort) consecutive patients with HCC treated over the same study period (2008-2015) who had complete restaging before decisions about additional therapies. The performance of the Italian Liver Cancer (ITA.LI.CA) prognostic score …

MaleOncologyDatabases FactualLiver cancer; non surgical therapy; prognostic system; surgical therapy; survivalhepatocellular carcinoma stage treatmentKaplan-Meier EstimateCohort StudiesLiver disease0302 clinical medicineMiddle AgedSorafenibPrognosisItaly030220 oncology & carcinogenesisCatheter AblationDisease ProgressionFemale030211 gastroenterology & hepatologysurgical therapyLiver cancerLiver cancermedicine.drugCohort studySorafenibmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIAClinical Decision-MakingRisk AssessmentsurvivalDisease-Free SurvivalStatistics Nonparametric03 medical and health sciencesnon surgical therapyInternal medicinemedicineHepatectomyHumansInfusions Intra-ArterialNeoplasm InvasivenessSurvival analysisAgedNeoplasm StagingRetrospective StudiesAnalysis of VarianceHepatologybusiness.industryprognostic systemReproducibility of ResultsCancerRetrospective cohort studymedicine.diseaseSurvival AnalysisbusinessProgressive disease
researchProduct

Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010

Anal cancer is strongly associated with human papilloma virus (HPV) infection. Using polymerase chain reaction (PCR), the presence of the HPV genome has been identified in 80%–85% of cases. Other important risk factors include human immunodeficiency virus (HIV), immune suppression in transplant recipients and cigarette smoking. Herpes simplex virus (HSV)may play a secondary role in disease progression.Dietaryhabits, chronic inflammatory diseases and the presence of haemorrhoids do not appear to predispose to epidermoid anal cancer. Previous (gynaecological, lymphoma or leukemia) or subsequent (e.g. lung, bladder, vulva, vagina or breast) malignancy is more likely in anal cancer patients. Th…

MaleOncologymedicine.medical_specialtyPalliative careAnal CarcinomaDiseaseMalignancyGastroenterologyMeta-Analysis as TopicRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineGenetic predispositionHumansAnal cancerNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingRandomized Controlled Trials as TopicSalvage TherapyRadiotherapybusiness.industryIncidencePalliative CareHPV infectionCancerHematologyAnus Neoplasmsmedicine.diseaseCombined Modality TherapyEuropeTreatment OutcomeOncologyFemalebusinessFollow-Up StudiesAnnals of Oncology
researchProduct

Liver transplantation for hepatocellular carcinoma with intrahepatic lymphatic invasion: case reports.

2008

Multiple studies addressing liver transplantation (OLT) for hepatocellular carcinoma (HCC) have identified various prognostic determinants of tumor recurrence and decreased patient survival. However, little information is available on the impact of intrahepatic lymphatic invasion on tumor recurrence and survival after OLT for HCC. Intrahepatic lymphatic invasion was observed in 1.4% (n = 2) of liver explants with HCC in our series. Both recipients are alive without tumor recurrence at 16 and 39 months post-OLT, respectively. Intrahepatic lymphatic invasion may not be an absolute adverse prognostic factor in cases of HCC with no hilar lymph node involvement at the time of OLT.

MalePathologymedicine.medical_specialtyCarcinoma HepatocellularLymphovascular invasionmedicine.medical_treatmentLiver transplantationGastroenterologyMetastasisInternal medicinemedicineHumansNeoplasm InvasivenessLymph nodeTransplantationbusiness.industryLiver NeoplasmsCancerMiddle Agedmedicine.diseasedigestive system diseasesLiver Transplantationsurgical procedures operativeLymphatic systemmedicine.anatomical_structureTreatment OutcomeHepatocellular carcinomaSurgeryFemaleLiver cancerbusinessTransplantation proceedings
researchProduct

Prognostic indicators for squamous cell carcinoma of the oral cavity: a clinicopathologic correlation.

1997

Fifty-three patients with T1 squamous cell cancer of the floor of mouth and ventral surface of the tongue with a known clinical outcome were retrospectively analyzed and arbitrarily divided into "aggressive" and "nonaggressive" groups based on their clinical behavior. Various host and tumor factors were then evaluated in an attempt to determine whether the tumor behavior could have been predicted. The paraffin-embedded tumor specimens were evaluated for tumor differentiation, tumor thickness and tumor invasion, microvessel density, and p53 expression. In addition, a composite morphologic grading score was obtained by combining cell differentiation, nuclear polymorphism, mitosis activity, de…

MalePathologymedicine.medical_specialtyCellular differentiationMitosisTongueCarcinomamedicineHumansNeoplasm InvasivenessGrading (tumors)Mouth FloorNeoplasm StagingRetrospective StudiesCell NucleusParaffin Embeddingbusiness.industryMicrocirculationRetrospective cohort studyCell DifferentiationMiddle Agedmedicine.diseaseGenes p53PrognosisTongue NeoplasmsGene Expression Regulation NeoplasticLymphatic systemmedicine.anatomical_structureTreatment OutcomeOtorhinolaryngologyEpidermoid carcinomaLymphatic MetastasisCarcinoma Squamous CellFemaleMouth NeoplasmsLymph NodesNeoplasm Recurrence LocalbusinessInfiltration (medical)Follow-Up StudiesForecastingThe Laryngoscope
researchProduct

Prognosis in lower lip squamous cell carcinoma: assessment of tumor factors.

1998

We studied a consecutive series of 54 cases of lower lip squamous cell carcinoma (LLSCC) in order to identify any variables which might predict the development of lymph node metastases. The cases were divided into 38 tumors without metastases (group I) and 16 tumors with lymph node metastases (group II). The following factors were investigated: tumor size, histologic grading maximal thickness, perineural invasion, DNA ploidy and PCNA expression. In conclusion, we found that LLSCC greater than 2 cm in diameter, with histological grading G3-G4, thickness of more than 6 mm, DNA aneuploidy and high PCNA expression (PCNA LI > 0.48), were at high risk for the development of lymph node metastases.

MalePathologymedicine.medical_specialtyLower lipPerineural invasionPathology and Forensic MedicineAge DistributionRisk FactorsProliferating Cell Nuclear AntigenCarcinomamedicineHumansBasal cellNeoplasm InvasivenessSex DistributionLymph nodeGrading (tumors)Dna ploidyAgedPloidiesbiologybusiness.industryCell BiologyDNA NeoplasmMiddle Agedmedicine.diseasePrognosisProliferating cell nuclear antigenmedicine.anatomical_structureLymphatic MetastasisLip Neoplasmsbiology.proteinCarcinoma Squamous CellFemalebusinessPathology, research and practice
researchProduct

Resection of the mesopancreas (RMP): a new surgical classification of a known anatomical space

2007

Abstract Background Prognosis after surgical therapy for pancreatic cancer is poor and has been attributed to early lymph node involvement as well as to a strong tendency of cancer cells to infiltrate into the retropancreatic tissue and to spread along the peripancreatic neural plexuses. The objective of our study was to classify the anatomical-surgical layer of the mesopancreas and to describe the surgical principles relevant for resection of the mesopancreas (RMP). Immunohistochemical investigation of the mesopancreatic-perineural lymphogenic structures was carried out with the purpose of identifying possible routes of metastatic spread. Methods Resection of the mesopancreas (RMP) was per…

MalePathologymedicine.medical_specialtymedicine.medical_treatmentlcsh:Surgerylcsh:RC254-282Sensitivity and SpecificityMesenteric VeinAnatomical spaceMesenteric VeinsPancreatectomyRisk FactorsPancreatic cancermedicineCadaverHumansNeoplasm InvasivenessLymph nodePancreasAgedAged 80 and overbusiness.industryResearchDissectionlcsh:RD1-811lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePancreatic NeoplasmsDissectionmedicine.anatomical_structureLymphatic systemOncologyPancreatectomySurgeryFemalebusinessPancreasWorld Journal of Surgical Oncology
researchProduct

Bladder tumor staging: comparison of contrast-enhanced and gray-scale ultrasound

2009

OBJECTIVE. The purpose of this study was to evaluate the effectiveness of contrast-enhanced sonography in comparison with conventional sonography in differentiating muscle- infiltrating and superficial neoplasms of the urinary bladder. SUBJECTS AND METHODS. Conventional and contrast-enhanced sonography were performed on 34 consecutively registered patients with bladder tumors. All examinations were reviewed by two independent sonologists. At gray-scale sonography, interruption of the hyperechoic bladder wall was considered the main diagnostic criterion for differentiating superficial and infiltrating tumors. At contrast-enhanced sonography, a tumor was considered superficial when the hypoen…

MalePathologymedicine.medical_specialtytumorUrinary systemcontrast agent; staging; tumor; ultrasonography; ultrasound; urinary bladderContrast MediaDiagnosis DifferentialImage Interpretation Computer-AssistedBladder tumorMedicineHumansRadiology Nuclear Medicine and imagingNeoplasm InvasivenessAgedNeoplasm StagingUrinary bladdermedicine.diagnostic_testbusiness.industryultrasoundUltrasoundGeneral MedicineCystoscopyCystoscopystagingultrasonographyMiddle Agedcontrast agentmedicine.diseaseBladder tumor stagingGray scale ultrasoundmedicine.anatomical_structureROC CurveUrinary Bladder NeoplasmsFemaleRadiologyDifferential diagnosisbusinessInfiltration (medical)urinary bladder
researchProduct

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

2015

Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects. While postprogression survival is clearly determined by the pattern of tumor progression, understanding the factors that drive prognosis in patients who discontinued sorafenib for any reason may help to improve patient management and second-line trial design. Patients consecutively admitted to three referral centers who were receiving best supportive care following permanent discontinuation of sorafenib for any reason were included. Postsorafenib survival (PSS) was calculated from the last day of treatmen…

MalePredictive Value of TestGastroenterologyCohort StudiesAntineoplastic AgentProspective StudiesProspective cohort studyMultivariate AnalysiLiver NeoplasmsHepatitis CMiddle AgedSorafenibItalyLiver NeoplasmHepatocellular carcinomaFemaleSurvival Analysimedicine.drugHumanSorafenibNiacinamidePhenylurea Compoundmedicine.medical_specialtyCarcinoma HepatocellularDrug-Related Side Effects and Adverse ReactionsSettore MED/12 - GASTROENTEROLOGIAReproducibility of ResultAntineoplastic AgentsRisk AssessmentPredictive Value of TestsInternal medicinemedicineHumansNeoplasm InvasivenessSurvival analysisAgedNeoplasm StagingNeoplasm InvasiveneAnalysis of VarianceHepatologyPerformance statusbusiness.industryPhenylurea CompoundsPatient SelectionCarcinomaSettore MED/09 - MEDICINA INTERNAReproducibility of ResultsHepatocellularHepatologymedicine.diseaseSurvival AnalysisSurgeryDiscontinuationProspective StudieWithholding TreatmentMultivariate AnalysisCohort StudiebusinessDrug-Related Side Effects and Adverse Reaction
researchProduct